Ara 290 vs Nandrolone
Extensively Studied vs FDA Approved
synergistic Mechanism-based · 50% Ara 290 and Nandrolone both promote healing through potentially complementary mechanisms. Often combined in healing protocols for enhanced tissue repair.
Molecular Data
Ara 290 Nandrolone
Weight 1,257 Da 274.40 Da (base)
Half-life ~20 minutes (SubQ), ~2 minutes (IV) ~6-12 days (decanoate)
Chain 11 amino acids —
Type Engineered peptide 19-nortestosterone steroid (C18H26O2)
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
Nandrolone
01 Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
02 Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
03 Increased bone mineral density through direct osteoblast stimulation
04 Improved nitrogen retention and protein synthesis for accelerated recovery
05 Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
06 Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
07 Clinically demonstrated efficacy in treating anemia of chronic renal failure
08 Potential neuroprotective properties observed in preclinical research
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
Nandrolone
100-200 mg/week (therapeutic) / 1x per week (decanoate) or 2-3x per week (NPP)
TRT Adjunct - Joint Support 50-100 mg/week 1x per week (decanoate)
Therapeutic - Anemia / Wasting 100-200 mg/week 1x per week (decanoate)
Performance Enhancement - Moderate 200-400 mg/week 1x per week (decanoate) or split into 2 injections
NPP Protocol - Shorter Cycle 200-350 mg/week Every other day or 3x per week
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
Nandrolone
Suppression of natural testosterone production (profoundly suppressive, more so than testosterone alone)
Water retention and bloating (less than testosterone at equianabolic doses)
Erectile dysfunction and reduced libido without concurrent testosterone ('deca dick')
Increased appetite and weight gain
Mild acne and oily skin (less pronounced than testosterone)
Elevated hematocrit and hemoglobin (erythrocytosis)
Injection site pain or discomfort
Mild mood changes (some users report increased emotional sensitivity)
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy (Category X - causes virilization of female fetus)
Nephrosis or the nephrotic phase of nephritis
Severe hepatic impairment
Hypercalcemia
Known hypersensitivity to nandrolone or any formulation components
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled heart failure or severe cardiovascular disease
Research Evidence
Ara 290 Nandrolone
Status Extensively Studied FDA Approved
References 5 studies 5 studies
Latest 2024 April 2005
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.